Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)
Recruiting · NCT06124586 · Interventional (participants receive a specific treatment) · Lead sponsor: Heinrich-Heine University, Duesseldorf
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The planned study is a Randomized Controlled Monocentric Trial, which will provide evidence on whether early angiography in percutaneous transluminal angioplasty (PTA) readiness ("immediate" treatment, within 48h) has advantages over the "standard of care", i.e., an elective procedure ("elective PTA") for the treatment of diabetic foot ulcer (DFU). The primary study endpoint is to investigate the impact of the "early PTA" within 48 hours on wound-healing assessed by wound area changes after PTA using a 3D-camera with artificial intelligence (AI)-based wound-analysis-system. The secondary endpoint is the effect of early PTA on the combined occurrence of major adverse limb (MALE) and cardiac events (MACE) over 12 months post-angioplasty using time-to-event analysis. Data will be collected at baseline, 24 hours, 1, 2, 3, 6, and 12 months after PTA. Diabetic kidney disease, distal symmetric polyneuropathy, retinopathy, cardiomyopathy, laboratory analyses, clinical scores, AI-based fundus photography, echocardiography, duplex sonography, and pulse oscillography will be assessed. Explanatory variables for wound healing are wound microbiome changes using whole-genome sequencing and oxygen saturation of the wound environment measured using near-infrared spectroscopy. Altered microbiome composition in ulcers can lead to severe local and systemic infections and complications, including major amputations. Nevertheless, the specific significance of the wound microbiome composition in chronic ischaemic ulcers in type 2 diabetes and the impact of PTA on the wound microbiome in type 2 diabetes is unclear. The exact timing for treating peripheral arterial disease (PAD) by revascularization in DFU after initial diagnosis is unknown and has yet to be fully understood.
Who can take part
Inclusion criteria
- volunteer adults
- written informed consent
- presence of known manifest T2D and fulfilment of the following criteria:
- HbA1c \< 10%
- presence of pAVD with fulfillment of the following criteria:
- PAD Stage After Fontaine IV (foot ulcer)
- Presence of foot ulcer with fulfillment of the following criteria:
- Foot ulceration without indication for emergency surgical care from stage Wagner 1.
- Age \>18 years
Exclusion criteria
- Acute leg ischemia (sudden onset, sensorimotor deficits, pale extremity, pain, loss of pulse, and shock).
- Type 1 diabetes mellitus (GADA, ICA, IA-2A, ZnT8A positive).
- Minors or subjects incapable of giving consent
- Pregnant or breastfeeding women
- Treatment with certain drugs (immunosuppressive therapy,
- Immunomodulators, chemotherapy, antibiotic therapy \< 2 weeks before
- intervention)
- Diseases of the pancreas
- Severe neurological or psychiatric disease
- Known presence of malignant tumor disease within the past 5 years
- Participation in other interventional trials and receipt of investigational medication within the last 30 days
- Blood or plasma donation within the last 3 months
Where it is running
1 location listed.
- University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular Medicine - Düsseldorf, Germany